Symbol Lookup

Friday February 12, 2016 2:32 AM ET. Data delayed 15 minutes.
7.21
0.06 (0.84%)
Bid/Lots
0.00/0
Ask/Lots
0.00/0
Open/Prev Close
6.94/7.15
Day Range
6.78-7.36
52-Week Range
6.51-23.61
Vol/Avg Daily Vol
286.0K/464.4K

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
No documents available

Peers Headlines

Feb 9, 2016

vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes
4:05PM ET on Tuesday Feb 09, 2016 by Business Wire
Companies Mentioned: VTVT

--Company expects to report topline results in mid-2016

vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzh...

Invitae Announces Full Year 2015 Financial Results and 2016 Business Objectives
4:00PM ET on Tuesday Feb 09, 2016 by Business Wire
Companies Mentioned: NVTA

-- Planning to deliver 50,000-70,000 billable tests and expand menu to approximately 3,000 genes by the end of 2016 --

-- Hosting conference call at 4:45 pm ET / 1:45 pm PT --

Invitae Corporation (NYSE: NVTA) today r...

Egalet to Present at BIO CEO & Investor Conference
6:00AM ET on Tuesday Feb 09, 2016 by PR Newswire
Companies Mentioned: EGLT

Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that Bob Radie, president ...

Feb 8, 2016

Egalet Seals Collaboration with Septodont to Promote SPRIX Nasal Spray to U.S. Dentists
11:12AM ET on Monday Feb 08, 2016 by MT Newswires
Companies Mentioned: EGLT
11:12 AM EST, 02/08/2016 (MT Newswires) -- Egalet Corp. (EGLT) said Monday morning it sealed a collaboration with Septodont under which Septodont will promote its SPRIX nasal spray exclusive to dentists in the U.S. using its specialty sales force...
Egalet Signs Agreement with Septodont, Inc. to Promote SPRIX(R) (ketorolac tromethamine) Nasal Spray to Dentists in United States
6:00AM ET on Monday Feb 08, 2016 by PR Newswire
Companies Mentioned: EGLT

Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agre...

Jan 28, 2016

vTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
4:05PM ET on Thursday Jan 28, 2016 by Business Wire
Companies Mentioned: VTVT

vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Steph...

Analyst Actions: Invitae Downgraded to Market Perform at Leerink Swann & Co.
11:26AM ET on Thursday Jan 28, 2016 by MT Newswires
Companies Mentioned: NVTA
11:26 AM EST, 01/28/2016 (MT Newswires) -- Invitae (NVTA) shares were downgraded to market perform from outperform at Leerink Swann & Co. Price: 6.82, Change: -0.34, Percent Change: -4.75 ...

Jan 26, 2016

Invitae to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on February 9, 2016
9:00AM ET on Tuesday Jan 26, 2016 by Business Wire
Companies Mentioned: NVTA

Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it will report its fourth quarter and year-end 2015 financial results on Tuesday, February 9, 2016, and Invitae's management team w...

Jan 21, 2016

vTv Therapeutics Starts Phase 2 Trial on TTP273 to Treat Type 2 Diabetes
2:44PM ET on Thursday Jan 21, 2016 by MT Newswires
Companies Mentioned: VTVT
02:44 PM EST, 01/21/2016 (MT Newswires) -- vTv Therapeutics (VTVT) shares were slightly higher on Thursday after the clinical-stage biopharmaceutical company said it has enrolled the first patients in a phase 2 study of its TTP273 in type 2 diabe...
vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
7:00AM ET on Thursday Jan 21, 2016 by Business Wire
Companies Mentioned: VTVT

--Topline results are expected at the end of 2016

vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer'...